IDEAYA Biosciences, Inc.
Every calculator, already run for IDYA
Open the full toolkit →You have the numbers on IDYA. Get the argument.
A written report on which of these readings actually decide the outcome for IDEAYA Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering IDYAAnalyst Price Target Disagreement for IDEAYA Biosciences, Inc.
Wall Street's bull case implies +80% from the current price; the bear case implies -14%. A 94% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for IDYA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydr…
IDYA — frequently asked
Is IDYA a buy right now?
Wall Street's consensus rating on IDEAYA Biosciences, Inc. is Strong Buy across 14 analysts, with a mean price target of $52.75 (+46% vs. the current $36.06). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is IDYA's next earnings date?
IDEAYA Biosciences, Inc. is next scheduled to report earnings around Nov 9, 2026. A full IDYA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for IDEAYA Biosciences, Inc.?
Analysts covering IDEAYA Biosciences, Inc. (IDYA) range from a bear-case target of $31.00 to a bull-case high of $65.00, with a mean consensus target of $52.75 across 12 analysts. The spread of $34.00 (94% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare IDEAYA Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For IDEAYA Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full IDYA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on IDEAYA Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.